Our proprietary OneBreath™ breath analysis system offers a much-needed alternative to current lung cancer screening and diagnostic methods. Our technology platform is intended to detect cancer by capturing and quantifying specific biomarkers in a patient's breath with enhanced accuracy in a portable, affordable, and easy to use system.1
Our mission is to save lives and make a significant impact on the global healthcare landscape, starting with early detection and diagnosis of lung cancer. We are dedicated to providing patients, healthcare professionals, and institutions with innovative, non-invasive, and cost-effective diagnostic screening solutions.
Our interdisciplinary team of experts includes engineers, scientists, and medical professionals who are passionate about creating life-saving solutions. Together, we strive to decrease the mortality rate of lung cancer through early detection, empowering patients and healthcare providers with the tools they need for a better tomorrow.
Dr. Victor van Berkel, MD, PhD is a Professor of Surgery in the Department of Cardiovascular and Thoracic Surgery at the University of Louisville, as well as Chief of the Division of Thoracic Surgery and is currently the vice-chair of the Department. He is a co-investigator for several oncologic clinical trials through the Brown Cancer Center, and sits on two FDA panels that deal with the approval of medical devices. In addition to his clinical practice, he has an active research lab - his research on the use of breath analysis to identify lung cancer led to him being a cofounder of Breath Diagnostics, Inc.
Founder and Director
Dr Bousamra is the Head of Thoracic Surgery for Ascension Health SE Michigan and a member of the American Association for Thoracic Surgery. He has authored over 50 peer-reviewed publications and holds several patents on methods to detect cancer.
Chairman and Director
Phillip B. Douglas has 40 years of experience as a seasoned and innovative leader who has management and board experience which spans diverse organizational settings and industries. In addition to serving as a Director of Breath Diagnostics, Mr. Douglas currently serves on the Board of Directors of Oceans Healthcare, PartnerCare, Ernest Healthcare, The Ear Nose Throat & Plastic Surgery Associates (“ENTPSA”), Palmetto Technology Group (“PTG”) and Volta Inc. Previously Phil was the Executive Chairman of KureSmart Pain Management and Chairman and CEO of LifeCare Health Partners, which operated 25 locations in 9 states and experienced significant revenue and earnings growth under Mr. Douglas’ leadership. Mr. Douglas previously held senior executive positions with Humana and United Healthcare. Mr. Douglas is a graduate of the University of Kentucky and was a CPA with Price Waterhouse Coopers.
Dr. Rich is currently the Cleveland Clinic’s Chairman of Operations and Strategy for the Sydell and Arnold Miller Family Heart & Vascular Institute. He previously served as the Surgical Director of the Sentara Cardiac Research Institute, as past President of the Society of Thoracic Surgeons and held leadership positions within the National Quality Forum (NQF). In addition, Dr. Rich served as the Director of the Center for Medicare at the Centers for Medicare and Medicaid Services (CMS). He testified four times before Congress and has served on Federal Advisory Committees for CMS as well as the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee.
CEO and Director
Ivan Lo is the founder of Wealth Stream Capital Corp, a family office that invests in private and public companies across various sectors. WSCC was formed as a result of the seed and early-stage investments Ivan Lo has made, which have led to multiple exits and companies that have surpassed unicorn valuations. Ivan has led multiple strategic financing initiatives, and has been instrumental in the success of numerous private and public companies, playing a key role in the structure and financing of companies across various sectors. He has funded over 100 private and public companies who collectively have raised over $1 billion.
See Our Work
OneBreath™ by Breath Diagnostics
OneBreath™ may save your life.
Contact us to discover the future of lung cancer screening or click below to learn more.1
1 : OneBreath™ is under development and has not yet been reviewed, evaluated, or approved by the U.S. Food and Drug Administration (FDA), or any other health authority or regulatory body worldwide. As such, OneBreath™ should not be considered available for use.
2 : The data, metrics, and statistics presented on this website, along with any other related communication materials, reflect preliminary research findings and clinical testing outcomes for the OneBreath™ product currently under development.Please note, these preliminary findings are not intended to serve as conclusive evidence of the safety, efficacy, or performance of OneBreath™, nor should they be interpreted as such.